Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
about
Toxicity and immunogenicity of Enterotoxigenic Escherichia coli heat-labile and heat-stable toxoid fusion 3xSTa(A14Q)-LT(S63K/R192G/L211A) in a murine model.Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice.Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity.Mucosal and systemic adjuvant activity of alphavirus replicon particles.Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum.Construction of prokaryotic expression system of ltB-ureB fusion gene and identification of the recombinant protein immunity and adjuvanticity.Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.Defining the immune response to Ehrlichia species using murine models.Oral vaccine delivery: can it protect against non-mucosal pathogens?Enterotoxigenic Escherichia coli heat-stable toxin and heat-labile toxin toxoid fusion 3xSTaN12S-dmLT induces neutralizing anti-STa antibodies in subcutaneously immunized mice.Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.The cholera toxin B subunit directly costimulates antigen-primed CD4+ T cells ex vivo.Analysis and application of a neutralizing linear epitope on liable toxin B of enterotoxin Escherichia coli.Nasal immunization with a fusion protein consisting of the hemagglutinin A antigenic region and the maltose-binding protein elicits CD11c(+) CD8(+) dendritic cells for induced long-term protective immunity.Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes.Evaluation of the adjuvant effect of Salmonella-based Escherichia coli heat-labile toxin B subunits on the efficacy of a live Salmonella-delivered avian pathogenic Escherichia coli vaccine.Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin.Colonization of gnotobiotic mice with human gut microflora at birth protects against Escherichia coli heat-labile enterotoxin-mediated abrogation of oral tolerance.Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin.The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response.
P2860
Q30416787-E053B635-671C-4E7D-9432-5BB3C4B7EEC0Q30952009-452E8A4F-1346-418F-BFDB-30558A6B3CB8Q33768109-2B0E913C-566E-4F2B-8AE0-FB04C396F3D8Q33870830-2B53D73F-E27C-47E8-99E6-6F19B3A52A6CQ34044951-BEAF4CB1-6F59-48C6-8100-77C4C0486481Q34301259-82C0D6E6-FEEC-4B72-A073-E29C60870180Q34410789-F3DD8712-547B-430A-AB45-90213DAB0FCAQ34761512-56F2346E-2EFC-4640-BFEC-8B7BCC1997E4Q35802015-A8841BD6-17F7-4945-AA29-4F3C4A3B08AEQ36065797-D74C6B55-DB68-4DFE-A09F-C9C5776D1494Q36710668-BE92A6F4-EFA1-40FD-90AA-C2A29269CC04Q37029697-18E0C936-2309-4FCC-992F-6566BEA1CC3AQ37229915-2683976A-B188-4E98-B294-1CAAB9BE9F59Q39218689-E73BD574-E0D5-48E1-AB7C-F862FB9029A4Q39656632-24C3CA2D-F405-44BB-BB35-7A06AA53653CQ40564857-2EE4154D-401A-4E9E-BB8F-E74CC0865CA0Q41400988-2594C474-785D-42F3-8732-CEDAFBEC1C06Q41873125-5D911515-045C-42F0-A5CB-347F0BEFF71BQ44663128-648F745A-5EC7-451A-85EC-AB004D9EB98CQ46602469-B35E0381-607A-4D7E-B691-0EC5EC918B5CQ47123471-8B9CD4F0-9FE0-4F80-9162-B4CC92FD3F59Q53921475-42329C3D-DA49-4324-91F5-702E7AA6928FQ54335551-93B8551C-EA2D-4DB5-9833-D5EB1DAF201EQ54337514-CA3F8065-A6A7-4576-9D97-8BA0100815E8
P2860
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@ast
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@en
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@nl
type
label
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@ast
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@en
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@nl
prefLabel
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@ast
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@en
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@nl
P2093
P2860
P1476
Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3083.2001.00883.X
P577
2001-03-01T00:00:00Z